Page 13 - Conjoint Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dup15q Syndrome Market Expected to Experience Steady Growth at a CAGR of 23.96% During the Study Period 20170-30 in the 7MM, says DelveInsight Soticlestat (OV935/TAK-935), is expected to get launched in the forecasted period (2021-2030). Soticlestat will enter the US Dup15q Syndrome market in 2024 and the EU and Japan Dup15q Syndrome market in 2025. USD 9.84 million in 2020 and is expected to rise in the forecast period. The Dup15q Syndrome market is expected to grow by factors like an increase in the patient pool, expected entry of emerging therapy, i.e., Soticlestat (OV935/TAK-935), and...

Among all the Chronic Pain emerging therapies, Rexlemestrocel (Gruenthal and Mesoblast) is expected to occupy the maximum share of the Chronic Pain market owing to promising efficacy signals shown in the phase II trial and also expected premium pricing.  Interested in knowing more about the report highlights? Get in touch @ Chronic pain is pain, which lasts for more than three months. The pain worsens with time and recurs at undefined periods of time. In normal cases, after healing pain subsidizes; however, in the case of Chronic Pain, the pain persists even after months of treating the ro...